| Business Summary | | Telik,
Inc.
is
a
biopharmaceutical
company
working
to
discover,
develop
and
commercialize
drugs
for
which
there
is
significant
demand
for
new
therapies.
The
Company's
most
advanced
product
development
programs
are
for
the
treatment
of
cancer
and
diabetes.
Telik's
efforts
are
concentrated
on
four
major
diseases:
cancer,
diabetes,
inflammatory
diseases
and
stroke.
The
Company's
two
most
advanced
product
candidates
are
for
cancer
treatment.
TLK286,
which
entered
clinical
trials
in
January
2000,
is
being
developed
for
the
treatment
of
chemotherapy-resistant
cancers.
TLK199,
a
small
molecule
that
accelerates
recovery
from
chemotherapy-induced
depletion
of
white
blood
cells,
or
neutropenia,
offers
a
potential
alternative
for
the
treatment
of
blood
disorders
associated
with
this
condition.
In
addition,
the
Company
has
discovered
novel
insulin
receptor
activators
for
the
treatment
of
Type
2
diabetes. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Telik,
Inc.
is
a
biopharmaceutical
company
working
to
discover,
develop,
and
commercialize
small
molecule
drugs
to
treat
serious
diseases
for
which
there
is
significant
demand
for
new
therapies.
For
the
six
months
ended
6/30/01,
revenues
fell
33%
to
$894
thousand.
Net
loss
applicable
to
Common
fell
38%
to
$7.9
million.
Revenues
reflect
the
recognition
of
deferred
contract
revenues
over
a
longer
period.
Lower
loss
reflects
the
absence
of
$4.7
million
in
preferred
stock
dividends. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Michael Wick, M.D., Ph.D., 55 Chairman,
Pres, CEO | $450K | -- | Cynthia Butitta, 46 CFO,
Chief Operating Officer | 125K | $38K | Jacqueline Dombroski, Ph.D. VP,
Regulatory Affairs and Quality Assurance | -- | -- | Reinaldo Gomez, Ph.D., 55 VP-Product
Devel. | 185K | -- | Graeme Martin, Ph.D. CTO | -- | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|